Activity Provided By:

Rush University Medical Center

Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

Overview / Abstract:	Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC. What are the latest data with these ADCs? Why is TROP2 an effective target in TNBC? How do we best incorporate these TROP2-targeted ADCs into TNBC care? This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment. This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC.
Expiration	Dec 23, 2022
Discipline(s)	Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME
Format	Webinar / Webcast / Video
Credits / Hours	1.0
Accreditation	ACCME and ANCC
Presenters / Authors / Faculty	Sara Hurvitz, MD, FACP Professor of Medicine University of California, Los Angeles (UCLA) Co-Director, Santa Monica-UCLA Outpatient Oncology Practice Medical Director, Clinical Research Unit Jonsson Comprehensive Cancer Center at UCLA Director of Breast Oncology Simms/Mann UCLA Center for Integrative Oncology Los Angeles, CA
Activity Specialities / Related Topics	OB/GYN / Women's Health, Oncology / Cancer / Radiation Therapy
Sponsors / Supporters / Grant Providers	Sponsored by Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL)
Keywords / Search Terms	ACHL Rush University Medical Center, triple negative breast cancer, TNBC, Trop2, antibody drug conjugate (ADC), oncologists, oncology, estrogen receptor, progesterone receptor, HER2, BRCA1/2, breast cancer, metastasis, relapse, African American, cytotoxic chemotherapy, anthracyclines, alkylators, taxanes, neoadjuvant chemotherapy, poly ADP-ribose polymerase (PARP) inhibitors, monoclonal antibody, transmembrane glycoprotein, PARP Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map